Low versus low-intermediate risk metastatic renal cell carcinoma (mRCC): Contemporary data from the International mRCC Database Consortium (IMDC).
Razane El Hajj Chehade(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Eddy Saad(Dana-Farber Cancer Institute), Rashad Nawfal(Dana-Farber Cancer Institute), Naveen S. Basappa, J. Connor Wells(Queen's University), Sumanta K. Pal(City of Hope), Renée Maria Saliby(Yale University), Sylvan C. Baca(Broad Institute), Karl Semaan(Broad Institute), Kosuke Takemura(Japanese Foundation For Cancer Research), Wanling Xie(Dana-Farber Cancer Institute), Marc Machaalani(Dana-Farber Cancer Institute), Cristina Suárez(Complejo Hospitalario de Salamanca), Clara Steiner(Dana-Farber Cancer Institute), Emre Yekedüz(Dana-Farber Cancer Institute), Marc Eid(Harvard University), Martín Zarbá(University of Calgary), Daniel Yick Chin Heng(University of Calgary), David Maj(University of Calgary)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k